Nina Saracen

Nina Saracen

Auto-generated profile, based on publicly available information

Nina Saracen

Academy of Silesia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
SCSandra Czyż
Sandra Czyż
NSNina Saracen
Nina Saracen
WMWiktoria Marszał
Wiktoria Marszał
KNKarolina Nowak
Karolina Nowak
WMWiktoria Mistarz
Wiktoria Mistarz
OSOliwia Sysło
Oliwia Sysło
Introduction and purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, involving not only joints but also internal organs, skin, and eyes. It is diagnosed in children under the age of 16 when symptoms last longer than six weeks. The ILAR classification includes several subtypes such as oligoarticular, polyarticular (RF-positive and RF-negative), systemic (sJIA), psoriatic, and enthesitis-related arthritis. Systemic JIA is characterized by fever and rash, while the oligoarticular form often coexists with positive ANA antibodies and carries a high risk of chronic uveitis. New subtypes have been added in recent years, such as early-onset ANA-positive JIA. Imaging, including X-ray, MRI, and ultrasound, plays a crucial role in assessing disease progression, especially in the hip, knee, and temporomandibular joints. Treatment involves a multidisciplinary approach and includes NSAIDs, intra-articular and systemic glucocorticoids, non-biologic DMARDs (especially methotrexate), and biological therapies. Biologic agents include TNF inhibitors (adalimumab, etanercept, infliximab), IL-1 inhibitors (anakinra, canakinumab), IL-6 inhibitor (tocilizumab), T-cell inhibitor (abatacept), and B-cell therapy (rituximab). These targeted treatments improve disease control, reduce joint damage, and enhance quality of life, enabling many patients to achieve remission and prevent long-term disability.

19 December 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
OSOliwia Sysło
Oliwia Sysło
WMWiktoria Marszał
Wiktoria Marszał
SCSandra Czyż
Sandra Czyż
NSNina Saracen
Nina Saracen
Introduction and Objective: Lyme disease is an infection caused by Gram-negative,microaerophilic spirochetes of the Borrelia genus, transmitted to humans through the bite ofan infected tick, which serves as the vector of this disease. It is one of the most frequentlydiagnosed tick-borne illnesses worldwide, with a rising incidence rate. Notably, childrenrepresent an increasingly affected population, emphasizing the need for focused attention onpediatric manifestations and management.Brief Overview of Current Knowledge - Lyme disease progresses through three clinicalstages: early localized, early disseminated, and late stage. Each phase presents withcharacteristic clinical manifestations. The early localized stage typically features erythema migrans, most often appearing onthe scalp, neck, shoulders, legs, or lower back. The early disseminated stage is marked by flu-likesymptoms, lymphadenopathy, arthralgia, myalgia, cranial nerve palsies—mostfrequently involving the facial nerve (cranial nerve VII) —ocular involvement,and lymphocytic meningitis. The late stage is characterized predominantly by pauciarticular arthritis, affecting largejoints—especially the knees. In some cases, cardiac manifestations may occur, suchas conduction abnormalities, myocarditis, or pericarditis.This progression underscores the multisystemic nature of Lyme disease and highlights theimportance of early recognition and treatment to prevent long-term complications.

12 January 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
WMWiktoria Marszał
Wiktoria Marszał
SCSandra Czyż
Sandra Czyż
NSNina Saracen
Nina Saracen
Introduction and Objective. Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterized by follicular occlusion, painful nodules, abscesses, sinus tract formation, and scarring, primarily affecting intertriginous areas. Although previously considered a disorder of the apocrine glands, HS is now recognized as a complex immunoinflammatory condition involving dysregulation of innate and adaptive immune pathways. This review aims to summarize current knowledge on the immunopathogenesis of HS, with particular emphasis on recent molecular and cellular insights relevant to targeted therapy. Brief Overview of Current Knowledge. The initiating event in HS is follicular hyperkeratosis, leading to follicular rupture and secondary inflammation. Disease progression is driven by persistent immune activation, dominated by Th1/Th17 polarization. Key mechanisms include increased expression of proinflammatory cytokines such as IL-17, IL-1β, TNF-α, and IFN-γ, activation of the complement system, especially C5a, and dysregulation of antimicrobial peptides. Aberrant interactions between keratinocytes, fibroblasts, plasma cells, innate lymphoid cells, and T-cell subsets contribute to chronic inflammation and tissue destruction. Summary. Hidradenitis suppurativa is a multifactorial immunoinflammatory disease in which follicular occlusion initiates a complex immune cascade. Identification of biomarkers and therapeutic targets, including IL-17-driven pathways, complement components, and CD2–CD58 signaling, supports the development of personalized, mechanism-based treatment strategies. Improved understanding of HS immunopathogenesis may enhance disease stratification and clinical outcomes.